首页 | 本学科首页   官方微博 | 高级检索  
     


Miyoshi myopathy and limb girdle muscular dystrophy R2 are the same disease
Authors:Ursula Moore  Heather Gordish  Jordi Diaz-Manera  Meredith K. James  Anna G. Mayhew  Michela Guglieri  Roberto Fernandez-Torron  Laura E. Rufibach  Jia Feng  Andrew M. Blamire  Pierre G. Carlier  Simone Spuler  John W. Day  Kristi J. Jones  Diana X. Bharucha-Goebel  Emmanuelle Salort-Campana  Alan Pestronk  Maggie C. Walter  Volker Straub
Affiliation:1. The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Central Parkway, Newcastle upon Tyne, United Kingdom;2. Center for Translational Science, Division of Biostatistics and Study Methodology, Children''s National Health System, Washington, DC, United States;3. Pediatrics, Epidemiology and Biostatistics, George Washington University, Washington, DC, United States;4. Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Barcelona, Spain;5. Neuromuscular Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau;6. The Jain Foundation, Seattle, Washington DC, United States;7. Magnetic Resonance Centre, Translational and Clinical Research Institute, Newcastle University, United Kingdom;8. AIM & CEA NMR Laboratory, Institute of Myology, Pitié-Salpêtrière University Hospital, 47-83 Paris, France;9. Charite Muscle Research Unit, Experimental and Clinical Research Center, a Joint Cooperation of the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine, Berlin, Germany;10. Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, United States;11. The Children''s Hospital at Westmead, and The University of Sydney, Australia;12. Department of Neurology Children''s National Health System, Washington, DC, United States;13. National Institutes of Health (NINDS), Bethesda, MD, United States;14. Service des maladies neuromusculaire et de la SLA, Hôpital de La Timone, Marseille, France;15. Department of Neurology Washington University School of Medicine, St. Louis, MO, United States;p. Friedrich-Baur-Institute, Department of Neurology, Ludwig-Maximilians-University of Munich, Germany;q. Neuromuscular Unit, Department of Neurology, Hospital U. Virgen del Rocío/Instituto de Biomedicina de Sevilla, Sevilla, Spain;r. Centre de référence des maladies neuromusculaires, Institut de Myologie, AP-HP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France;s. Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry Tokyo, Japan;t. Neuroscience Institute, Carolinas Neuromuscular/ALS-MDA Center, Carolinas HealthCare System, Charlotte, NC, United States;u. Department of Neuroscience, University of Padova, Italy;v. The Abigail Wexner Research Institute at Nationwide Children''s Hospital, Columbus, OH United States
Abstract:This study aims to determine clinically relevant phenotypic differences between the two most common phenotypic classifications in dysferlinopathy, limb girdle muscular dystrophy R2 (LGMDR2) and Miyoshi myopathy (MMD1). LGMDR2 and MMD1 are reported to involve different muscles, with LGMDR2 showing predominant limb girdle weakness and MMD1 showing predominant distal lower limb weakness. We used heatmaps, regression analysis and principle component analysis of functional and Magnetic Resonance Imaging data to perform a cross-sectional review of the pattern of muscle involvement in 168 patients from the Jain Foundation's international Clinical Outcomes Study for Dysferlinopathy. We demonstrated that there is no clinically relevant difference in proximal vs distal involvement between diagnosis. There is a continuum of distal involvement at any given degree of proximal involvement and patients do not fall into discrete distally or proximally affected groups. There appeared to be geographical preference for a particular diagnosis, with MMD1 being more common in Japan and LGMDR2 in Europe and the USA. We conclude that the dysferlinopathies do not form two distinct phenotypic groups and therefore should not be split into separate cohorts of LGMDR2 and MM for the purposes of clinical management, enrolment in clinical trials or access to subsequent treatments.
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号